# US 2014/0154251 A1 · Anti c-met antibody and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2014/0154251 A1
- Document ID: US20140154251A1
- Status: Published application
- Kind: A1
- Application number: 14/081,917
- Filed: 2013-11-15
- Published: 2014-06-05
- Earliest claimed: 2011-10-05
- Assignees: Samsung Electronics Co., Ltd.
- Applicants: Samsung Electronics Co., Ltd.
- Inventors: Seung Hyun LEE; Geun Woong Kim; Kyung Ah Kim; Hye Won Park; Ho Yeong Song; Young Mi Oh; Saet Byoul Lee; Ji Min Lee; Kwang Ho Cheong; Yun Ju Jeong; Mi Young Cho; Jae Hyun Choi; Yun Jeong Song; Yoon Aa Choi
- Web page: https://patentgrep.com/patent/US20140154251A1

## CPC

- C07K 16/2863: {against receptors for growth factors, growth regulators}
- A61K 2039/505: {comprising antibodies}
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/52: Constant or Fc region; Isotype
- C07K 2317/53: Hinge
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/622: Single chain antibody (scFv)
- C07K 2317/73: Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

An anti-c-Met antibody or antibody fragment and pharmaceutical composition comprising same, as well as a method for preventing and treating cancer by administering the antibody to a subject are provided.

## Claims

### Claim 1

A method of prevention or treatment of a cancer comprising administering an anti-c-Met or an antigen-binding fragment thereof to a subject in need of prevention or treatment of the cancer.

### Claim 2 (depends on 1)

The method of claim 1, wherein the anti-c-Met antibody or antigen-binding fragment thereof comprising:
a heavy chain variable region comprising at least one heavy chain complementarity determining region (CDR) selected from the group consisting of CDR-H1 having an amino acid sequence of SEQ ID NO: 1 or SEQ ID NO: 4, CDR-H2 having an amino acid sequence of SEQ ID NO: 2 or SEQ ID NO: 5, and CDR-H3 having an amino acid sequence of SEQ ID NO: 3 or SEQ ID NO: 6; and
a light chain variable region comprising at least one light chain CDR selected from the group consisting of CDR-L1 having an amino acid sequence of SEQ ID NO: 7, CDR-L2 having an amino acid sequence of SEQ ID NO: 8, and CDR-L3 having an amino acid sequence of SEQ ID NO: 9, wherein SEQ ID NOS: 4 to 9 are respectively represented by following Formula I to VI:
Xaa1-Xaa2-Tyr-Tyr-Met-Ser (SEQ ID NO: 4), wherein Xaa1 is Pro or Ser or is absent, and Xaa2 is Glu or Asp; Formula I
Arg-Asn-Xaa3-Xaa4-Asn-Gly-Xaa5-Thr (SEQ ID NO: 5), wherein Xaa3 is Asn or Lys, Xaa4 is Ala or Val, and Xaa5 is Asn or Thr; Formula II
Asp-Asn-Trp-Leu-Xaa6-Tyr (SEQ ID NO: 6); wherein Xaa6 is Ser or Thr; Formula III
Lys-Ser-Ser-Xaa7-Ser-Leu-Leu-Ala-Xaa8-Gly-Asn-Xaa9-Xaa10-Asn-Tyr-Leu-Ala (SEQ ID NO: 7), wherein Xaa7 is His, Arg, Gln, or Lys, Xaa8 is Ser or Trp, Xaa9 is His or Gln, and Xaa10 is Lys or Asn; Formula IV
Trp-Xaa11-Ser-Xaa12-Arg-Val-Xaa13 (SEQ ID NO: 8), wherein Xaa11 is Ala or Gly, Xaa12 is Thr or Lys, and Xaa13 is Ser or Pro; and Formula V
Xaa14-Gln-Ser-Tyr-Ser-Xaa15-Pro-Xaa16-Thr (SEQ ID NO: 9), wherein Xaa14 is Gly, Ala, or Gln, Xaa15 is Arg, His, Ser, Ala, Gly, or Lys, and Xaa16 is Leu, Tyr, Phe, or Met. Formula VI

### Claim 3 (depends on 2)

The method of claim 2, wherein,
the CDR-H1 a polypeptide having an amino acid sequence of SEQ ID NO: 22, 23, or 24; the CDR-H2 is a polypeptide having an amino acid sequence of SEQ ID NO: 25 or 26.; the CDR-H3 is a polypeptide having an amino acid sequence of SEQ ID NO: 27 or 28; the CDR-L1 is a polypeptide having an amino acid sequence of SEQ ID NO: 29, 30, 31, 32, 33, or 71; the CDR-L2 is a polypeptide having an amino acid sequence of SEQ ID NO: 34, 35, or 36; or the CDR-L3 is a polypeptide having an amino acid sequence of SEQ ID NO: 13, 14, 15, 16, or 37.

### Claim 4 (depends on 1)

The method of claim 1, wherein the anti-c-Met antibody or antigen-binding fragment thereof comprising:
a heavy chain variable region comprising at least one heavy chain complementarity determining region (CDR) selected from the group consisting of CDR-H1 having an amino acid sequence of SEQ ID NO: 1, CDR-H2 having an amino acid sequence of SEQ ID NO: 2, and CDR-H3 having an amino acid sequence of SEQ ID NO: 3; and
a light chain variable region comprising at least one light chain CDR selected from the group consisting of CDR-L1 having an amino acid sequence of SEQ ID NO: 7, CDR-L2 having an amino acid sequence of SEQ ID NO: 8, and CDR-L3 having an amino acid sequence of SEQ ID NO: 9, wherein SEQ ID NOS: 7 to 9 are respectively represented by Formula IV to VI below:
Lys-Ser-Ser-Xaa7-Ser-Leu-Leu-Ala-Xaa8-Gly-Asn-Xaa9-Xaa10-Asn-Tyr-Leu-Ala (SEQ ID NO: 7), wherein Xaa7 is His, Arg, Gln, or Lys, Xaa8 is Ser or Trp, Xaa9 is His or Gln, and Xaa10 is Lys or Asn; Formula IV
Trp-Xaa11-Ser-Xaa12-Arg-Val-Xaa13 (SEQ ID NO: 8), wherein Xaa11 is Ala or Gly, Xaa12 is Thr or Lys, and Xaa13 is Ser or Pro; and Formula V
Xaa14-Gln-Ser-Tyr-Ser-Xaa15-Pro-Xaa16-Thr (SEQ ID NO: 9), wherein Xaa14 is Gly, Ala, or Gln, Xaa15 is Arg, His, Ser, Ala, Gly, or Lys, and Xaa16 is Leu, Tyr, Phe, or Met. Formula VI

### Claim 5 (depends on 4)

The method of claim 4, wherein the anti-c-Met antibody or antigen-binding fragment thereof comprises the light chain variable region comprises at least one light chain CDR selected from the group consisting of CDR-L1 having an amino acid sequence of SEQ ID NO: 10 or 71, CDR-L2 having an amino acid sequence of SEQ ID NO: 11, and CDR-L3 having an amino acid sequence of SEQ ID NO: 13, 14, 15, or 16.

### Claim 6 (depends on 4)

The method of claim 4, wherein the anti-c-Met antibody or antigen-binding fragment thereof comprises the heavy chain variable region has an amino acid sequence of SEQ ID NO: 17, and the light chain variable region has an amino acid sequence of SEQ ID NO: 18, 19, 20, 21, or 72.

### Claim 7 (depends on 1)

The method of claim 1, wherein the anti-c-Met antibody or antigen-binding fragment thereof comprises:
a heavy chain comprising an amino acid sequence from 18th to 462nd of SEQ ID NO: 62, an amino acid sequence from 18th to 461st of SEQ ID NO: 64, or amino acid sequence from 18th to 460th of SEQ ID NO: 66, and a light chain comprising an amino acid sequence from 21st to 220th of SEQ ID NO: 68;
a heavy chain comprising an amino acid sequence from 18th to 462nd of SEQ ID NO: 62, an amino acid sequence from 18th to 461st of SEQ ID NO: 64, or amino acid sequence from 18th to 460th of SEQ ID NO: 66, and a light chain comprising an amino acid sequence from 21st to 220th of SEQ ID NO: 70; or
a heavy chain comprising an amino acid sequence from 18th to 462nd of SEQ ID NO: 62, an amino acid sequence from 18th to 461st of SEQ ID NO: 64, or amino acid sequence from 18th to 460th of SEQ ID NO: 66, and a light chain comprising an amino acid sequence of SEQ ID NO: 73.

### Claim 8 (depends on 1)

The method of claim 1, wherein the anti-c-Met antibody or antigen-binding fragment thereof comprises an amino acid sequence of SEQ ID NO: 71, 72, or 73.

### Claim 9 (depends on 1)

The method of claim 1, wherein the antibody or antigen-binding fragment is a monoclonal antibody, a mouse-derived antibody, a mouse-human chimeric antibody, or a humanized antibody,

### Claim 10 (depends on 1)

The method of claim 1, wherein the antigen-binding fragment is scFv, (scFv)2, Fab, Fab′, or F(ab′)2.

### Claim 11

A method of prevention or inhibition of metastasis of a cancer comprising administering an anti-c-Met or an antigen-binding fragment thereof to a subject in need of prevention or treatment of the cancer.

### Claim 12 (depends on 11)

The method of claim 11, wherein the anti-c-Met antibody or antigen-binding fragment thereof comprising:
a heavy chain variable region comprising at least one heavy chain complementarity determining region (CDR) selected from the group consisting of CDR-H1 having an amino acid sequence of SEQ ID NO: 1 or SEQ ID NO: 4, CDR-H2 having an amino acid sequence of SEQ ID NO: 2 or SEQ ID NO: 5, and CDR-H3 having an amino acid sequence of SEQ ID NO: 3 or SEQ ID NO: 6; and
a light chain variable region comprising at least one light chain CDR selected from the group consisting of CDR-L1 having an amino acid sequence of SEQ ID NO: 7, CDR-L2 having an amino acid sequence of SEQ ID NO: 8, and CDR-L3 having an amino acid sequence of SEQ ID NO: 9, wherein SEQ ID NOS: 4 to 9 are respectively represented by following Formula I to VI:
Xaa1-Xaa2-Tyr-Tyr-Met-Ser (SEQ ID NO: 4), wherein Xaa1 is Pro or Ser or is absent, and Xaa2 is Glu or Asp; Formula I
Arg-Asn-Xaa3-Xaa4-Asn-Gly-Xaa5-Thr (SEQ ID NO: 5), wherein Xaa3 is Asn or Lys, Xaa4 is Ala or Val, and Xaa5 is Asn or Thr; Formula II
Asp-Asn-Trp-Leu-Xaa6-Tyr (SEQ ID NO: 6); wherein Xaa6 is Ser or Thr; Formula III
Lys-Ser-Ser-Xaa7-Ser-Leu-Leu-Ala-Xaa8-Gly-Asn-Xaa9-Xaa10-Asn-Tyr-Leu-Ala (SEQ ID NO: 7), wherein Xaa7 is His, Arg, Gln, or Lys, Xaa8 is Ser or Trp, Xaa9 is His or Gln, and Xaa10 is Lys or Asn; Formula IV
Trp-Xaa11-Ser-Xaa12-Arg-Val-Xaa13(SEQ ID NO: 8), wherein Xaa11 is Ala or Gly, Xaa12 is Thr or Lys, and Xaa13 is Ser or Pro; and Formula V
Xaa14-Gln-Ser-Tyr-Ser-Xaa15-Pro-Xaa16-Thr (SEQ ID NO: 9), wherein Xaa14 is Gly, Ala, or Gln, Xaa15 is Arg, His, Ser, Ala, Gly, or Lys, and Xaa16 is Leu, Tyr, Phe, or Met. Formula VI

### Claim 13 (depends on 12)

The method of claim 12, wherein,
the CDR-H1 a polypeptide having an amino acid sequence of SEQ ID NO: 22, 23, or 24; the CDR-H2 is a polypeptide having an amino acid sequence of SEQ ID NO: 25 or 26.; the CDR-H3 is a polypeptide having an amino acid sequence of SEQ ID NO: 27 or 28; the CDR-L1 is a polypeptide having an amino acid sequence of SEQ ID NO: 29, 30, 31, 32, 33, or 71; the CDR-L2 is a polypeptide having an amino acid sequence of SEQ ID NO: 34, 35, or 36; or the CDR-L3 is a polypeptide having an amino acid sequence of SEQ ID NO: 13, 14, 15, 16, or 37.

### Claim 14 (depends on 11)

The method of claim 11, wherein the anti-c-Met antibody or antigen-binding fragment thereof comprising:
a heavy chain variable region comprising at least one heavy chain complementarity determining region (CDR) selected from the group consisting of CDR-H1 having an amino acid sequence of SEQ ID NO: 1, CDR-H2 having an amino acid sequence of SEQ ID NO: 2, and CDR-H3 having an amino acid sequence of SEQ ID NO: 3; and
a light chain variable region comprising at least one light chain CDR selected from the group consisting of CDR-L1 having an amino acid sequence of SEQ ID NO: 7, CDR-L2 having an amino acid sequence of SEQ ID NO: 8, and CDR-L3 having an amino acid sequence of SEQ ID NO: 9, wherein SEQ ID NOS: 7 to 9 are respectively represented by Formula IV to VI below:
Lys-Ser-Ser-Xaa7-Ser-Leu-Leu-Ala-Xaa8-Gly-Asn-Xaa9-Xaa10-Asn-Tyr-Leu-Ala (SEQ ID NO: 7), wherein Xaa7 is His, Arg, Gln, or Lys, Xaa8 is Ser or Trp, Xaa9 is His or Gln, and Xaa10 is Lys or Asn; Formula IV
Trp-Xaa11-Ser-Xaa12-Arg-Val-Xaa13(SEQ ID NO: 8), wherein Xaa11 is Ala or Gly, Xaa12 is Thr or Lys, and Xaa13 is Ser or Pro; and Formula V
Xaa14-Gln-Ser-Tyr-Ser-Xaa15-Pro-Xaa16-Thr (SEQ ID NO: 9), wherein Xaa14 is Gly, Ala, or Gln, Xaa15 is Arg, His, Ser, Ala, Gly, or Lys, and Xaa16 is Leu, Tyr, Phe, or Met. Formula VI

### Claim 15 (depends on 14)

The method of claim 14, wherein the anti-c-Met antibody or antigen-binding fragment thereof comprises the light chain variable region comprises at least one light chain CDR selected from the group consisting of CDR-L1 having an amino acid sequence of SEQ ID NO: 10 or 71, CDR-L2 having an amino acid sequence of SEQ ID NO: 11, and CDR-L3 having an amino acid sequence of SEQ ID NO: 13, 14, 15, or 16.

### Claim 16 (depends on 14)

The method of claim 14, wherein the anti-c-Met antibody or antigen-binding fragment thereof comprises the heavy chain variable region has an amino acid sequence of SEQ ID NO: 17, and the light chain variable region has an amino acid sequence of SEQ ID NO: 18, 19, 20, 21, or 72.

### Claim 17 (depends on 11)

The method of claim 11, wherein the anti-c-Met antibody or antigen-binding fragment thereof comprises:
a heavy chain comprising an amino acid sequence from 18th to 462nd of SEQ ID NO: 62, an amino acid sequence from 18th to 461st of SEQ ID NO: 64, or amino acid sequence from 18th to 460th of SEQ ID NO: 66, and a light chain comprising an amino acid sequence from 21st to 220th of SEQ ID NO: 68;
a heavy chain comprising an amino acid sequence from 18th to 462nd of SEQ ID NO: 62, an amino acid sequence from 18th to 461st of SEQ ID NO: 64, or amino acid sequence from 18th to 460th of SEQ ID NO: 66, and a light chain comprising an amino acid sequence from 21st to 220th of SEQ ID NO: 70; or
a heavy chain comprising an amino acid sequence from 18th to 462nd of SEQ ID NO: 62, an amino acid sequence from 18th to 461st of SEQ ID NO: 64, or amino acid sequence from 18th to 460th of SEQ ID NO: 66, and a light chain comprising an amino acid sequence of SEQ ID NO: 73.

### Claim 18 (depends on 11)

The method of claim 11, wherein the anti-c-Met antibody or antigen-binding fragment thereof comprises an amino acid sequence of SEQ ID NO: 71, 72, or 73.

### Claim 19 (depends on 11)

The method of claim 11, wherein the antibody or antigen-binding fragment is a monoclonal antibody, a mouse-derived antibody, a mouse-human chimeric antibody, or a humanized antibody,

### Claim 20 (depends on 11)

The method of claim 11, wherein the antigen-binding fragment is scFv, (scFv)2, Fab, Fab′, or F(ab′)2.
